(RTTNews) – Shares of Sarepta Therapeutics (SRPT) surged approximately 47% in after-hours trading on NasdaqGS after the U.S. Food and Drug Administration recommended lifting the voluntary hold on the company’s gene therapy, Elevidys, for ambulatory patients with Duchenne Muscular